Mon, March 14, 2022

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $130 on, Mar 14th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-130-on-mar-14th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $140 to $130 on, Mar 14th, 2022.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $25 on, Wednesday, February 16th, 2022
  • Corinne Jenkins of "Goldman Sachs" Downgraded from Strong Buy to Strong Sell and Decreased Target to $24 on, Monday, November 15th, 2021